Catalog Home Page

Nucleic acid-based theranostics for tackling Alzheimer's Disease

Chakravarthy, M., Chen, S., Dodd, P.R. and Veedu, R.N. (2017) Nucleic acid-based theranostics for tackling Alzheimer's Disease. Theranostics, 7 (16). pp. 3933-3947.

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
Free to read: https://doi.org/10.7150/thno.21529
*No subscription required

Abstract

Nucleic acid-based technologies have received significant interest in recent years as novel theranostic strategies for various diseases. The approval by the United States Food and Drug Administration ( FDA) of Nusinersen, an antisense oligonucleotide drug, for the treatment of spinal muscular dystrophy highlights the potential of nucleic acids to treat neurological diseases, including Alzheimer's disease (AD). AD is a devastating neurodegenerative disease characterized by progressive impairment of cognitive function and behavior. It is the most common form of dementia; it affects more than 20% of people over 65 years of age and leads to death 7-15 years after diagnosis. Intervention with novel agents addressing the underlying molecular causes is critical. Here we provide a comprehensive review on recent developments in nucleic acid-based theranostic strategies to diagnose and treat AD.

Publication Type: Journal Article
Murdoch Affiliation: Centre for Comparative Genomics
Publisher: Ivyspring International Publisher
URI: http://researchrepository.murdoch.edu.au/id/eprint/38637
Item Control Page Item Control Page

Downloads

Downloads per month over past year